Zerviate available in US for allergic conjunctivitis
Cetirizine ophthalmic solution (Zerviate; Eyevance Pharmaceuticals) is available in the United States for the treatment of ocular itching associated with allergic conjunctivitis, according to a press release.
In clinical trials, the solution demonstrated rapid ocular itching relief and relieved ocular allergic conjunctivitis symptoms more quickly than systemic antihistamines. In patients with moderate and severe allergic conjunctivitis, it was found to relieve ocular itching for 8 hours.
“Zerviate’s unique formulation and impressive clinical profile makes it an attractive treatment option for patients who present with allergic conjunctivitis,” Michael Raizman, MD, Associate Professor of Ophthalmology at Tufts University School of Medicine, and private practice at Ophthalmic Consultants of Boston, said in a company news release. “Cetirizine is a well-established treatment for allergic inflammation. Its availability in a topical form facilitates localized, targeted treatment – which can have significant patient benefits over systemic options. The clinical trial data were impressive. I look forward to prescribing Zerviate for patients with itchy, allergic eyes.”
Read the full press release here.
